Active substance
Results for the substance inotuzumab ozogamycin
1 result
About this active substance
Inotuzumab ozogamicin is a medication used for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). It is a monoclonal antibody conjugated to a cytotoxic agent, targeting CD22-expressing cancer cells and destroying them.
The medication is administered intravenously, as directed by a doctor, usually in treatment cycles. It is important for patients to be monitored to prevent adverse reactions and to assess the response to therapy.
Patients should be aware of potential side effects, such as fever, nausea, or a decrease in blood cell counts. It is important to inform the doctor of any unusual symptoms.
Common side effects include fever, nausea, and a decrease in blood cell counts. In rare cases, severe reactions such as hepatotoxicity or veno-occlusive disease may occur. Patients should be informed of these risks before administration.
The medication is administered intravenously, as directed by a doctor, usually in treatment cycles. It is important for patients to be monitored to prevent adverse reactions and to assess the response to therapy.
Patients should be aware of potential side effects, such as fever, nausea, or a decrease in blood cell counts. It is important to inform the doctor of any unusual symptoms.
Common side effects include fever, nausea, and a decrease in blood cell counts. In rare cases, severe reactions such as hepatotoxicity or veno-occlusive disease may occur. Patients should be informed of these risks before administration.